Stage 2 cardiovascular-kidney-metabolic syndrome and the risk of heart failure

9 May 2026 (13:30 - 14:15)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Kanako Teramoto

National Cerebral and Cardiovascular Center Hospital, Osaka (Japan)

5 More presentations in this session

Presentation thumbnail

The GLP-1 receptor agonist Semaglutide preserves cardiac function, reduces inflammation-driven cardiotoxicity with cardio-renal benefits in non-diabetic models exposed to anthracyclines and HER2 block

Doctor V. Quagliariello (Naples, IT)

Abstract Slides

Presentation thumbnail

Drug therapy in patients with heart failure with reduced left ventricular ejection fraction and chronic kidney disease stages 4-5: a medical challenge.

Doctor M. Anguita Sanchez (Cordoba, ES)

Abstract Slides

Presentation thumbnail

Non conventional risc factors for coronary heart disease in end stage renal disease patients.

Doctor E. Shkembi (Vlora, AL)

Abstract Slides

Presentation thumbnail

Association of albuminuria with left atrial remodeling and left ventricular diastolic function in non-dialysis chronic kidney disease patients

Associate Professor S. Murat (Eskisehir, TR)

Abstract Slides

Presentation thumbnail

Finerenone and all-cause hospitalization in cardiovascular-kidney-metabolic disease

Doctor J. Ostrominski (Boston, US)

Abstract Slides

Access the full session

Session thumbnail

CKM syndrome in practice: risk, mechanisms, and therapy

The Event

Event poster

Heart Failure 2026

9 May 2026 13:30 CET

You may be interested in

Webinar

Prevention of heart failure in diabetic patients at population level

Congress Session

Diabetes, obesity, and heart failure

Webinar

Diabetes and ACS - enhancing post-discharge outcomes after primary PCI

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources